15th Oct 2025 13:17
(Alliance News) - RTW Biotech Opportunities Ltd said on Wednesday that it invested USD7.4 million in Kailera Therapeutics Inc for the company's USD600 million Series B financing round.
RTW Biotech, a London-listed investor focused on high-growth life science assets, said the investment will "support the advancement of Kailera's leading obesity portfolio", including a global Phase 3 clinical program of its lead product candidate KAI-9531.
Kailera's Series B financing round was led by its new investor Bain Capital Private Equity, with additional new investors comprising leading mutual funds and investors.
RTW Bio invested 1.4 times more in Kailera than in its Series A financing round. As of September 30, Kailera represented 4.0% of RTW Bio's net asset value.
RTW Biotech said the Massachusetts, US-based obesity-focused therapy company Kailera's KAI-9531 is a novel dual GLP-1/GIP receptor agonist with "potentially best-in-category weight loss".
The financing will also advance KAI-7535, an oral small molecule GLP-1 receptor agonist that demonstrated competitive weight loss in a Phase 2 clinical trial in China, to global clinical trials.
Chief Information Officer Rod Wong said: "Our further investment in Kailera reflects our strong conviction in the obesity space, where we're seeing growing momentum. Around 40% of RTW Bio's private portfolio exposure comprises companies focused on next-generation obesity treatments and this financing round demonstrates the strong interest in the space and value in our private assets, especially when combined with the recently announced acquisition of Metsera by Pfizer.
"Kailera's lead program, KAI-9531, is advancing into global Phase 3 trials with data that suggest best-in-category potential. Combined with a broad pipeline and strong execution, Kailera is positioned to be a key player in the next wave of obesity innovation."
Shares in RTW Biotech rose 1.3% to USD1.61 on Wednesday afternoon in London.
By Roya Shahidi, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
Rtw Biotech